CRNX Crinetics Pharmaceuticals, Inc. revenue, earnings and financials

For the quarter ended June 30, 2026, Crinetics Pharmaceuticals, Inc. reported revenue of $25.1M (up 2336.3% from a year earlier), net income of −$121M and diluted EPS of −$1.14; over the last four quarters revenue was $42.2M and net income −$502M; for the fiscal year ended December 2025 revenue was $7.70M, up 640.7% on the year before.

CRNX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $7.70M, gross profit n/a, operating income −$517M, net income −$465M (margin -6046.0%), EPS −$4.95
• Fiscal year ended Dec 2024: revenue $1.04M, gross profit n/a, operating income −$339M, net income −$298M (margin -28719.9%), EPS −$3.69
• Fiscal year ended Dec 2023: revenue $4.01M, gross profit n/a, operating income −$223M, net income −$215M (margin -5345.1%), EPS −$3.69
• Fiscal year ended Dec 2022: revenue $4.74M, gross profit n/a, operating income −$168M, net income −$164M (margin -3460.0%), EPS −$3.15
• Fiscal year ended Dec 2021: revenue $1.08M, gross profit n/a, operating income −$108M, net income −$108M (margin -9981.4%), EPS −$2.80

CRNX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $25.1M (up 2336.3% year over year), net income −$121M, EPS −$1.14
• Quarter ended Mar 31, 2026: revenue $10.7M (up 2873.4% year over year), net income −$128M, EPS −$1.23
• Quarter ended Dec 31, 2025 (from the annual report): revenue $6.16M, net income −$123M, EPS −$1.30
• Quarter ended Sep 30, 2025: revenue $143K, net income −$130M, EPS −$1.38
• Quarter ended Jun 30, 2025: revenue $1.03M (up 158.4% year over year), net income −$116M, EPS −$1.23
• Quarter ended Mar 31, 2025: revenue $361K (down 43.6% year over year), net income −$96.8M, EPS −$1.04
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$80.6M, EPS −$0.86
• Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$76.8M, EPS −$0.96
• Quarter ended Jun 30, 2024: revenue $399K (down 59.6% year over year), net income −$74.1M, EPS −$0.94
• Quarter ended Mar 31, 2024: revenue $640K (down 76.1% year over year), net income −$66.9M, EPS −$0.93
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income −$60.1M, EPS −$0.89
• Quarter ended Sep 30, 2023: revenue $346K (down 24.5% year over year), net income −$57.5M, EPS −$1.01
• Quarter ended Jun 30, 2023: revenue $988K (up 125.1% year over year), net income −$51.0M, EPS −$0.94
• Quarter ended Mar 31, 2023: revenue $2.68M (down 14.4% year over year), net income −$46.0M, EPS −$0.85
• Quarter ended Dec 31, 2022 (from the annual report): revenue $709K, net income −$45.0M, EPS −$0.83
• Quarter ended Sep 30, 2022: revenue $458K, net income −$41.9M, EPS −$0.78
• Quarter ended Jun 30, 2022: revenue $439K, net income −$42.4M, EPS −$0.81
• Quarter ended Mar 31, 2022: revenue $3.13M, net income −$34.6M, EPS −$0.73
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$30.8M, EPS −$0.68
• Quarter ended Sep 30, 2021: revenue $0, net income −$27.9M, EPS −$0.73

CRNX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$378M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$230M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$169M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$115M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$88.6M, share buybacks n/a

CRNX balance sheet

• Jun 30, 2026: cash $55.5M, total assets $1.32B, total liabilities $130M, shareholders' equity $1.19B
• Mar 31, 2026: cash $114M, total assets $1.40B, total liabilities $121M, shareholders' equity $1.28B
• Dec 31, 2025: cash $102M, total assets $1.13B, total liabilities $134M, shareholders' equity $992M
• Sep 30, 2025: cash $111M, total assets $1.20B, total liabilities $124M, shareholders' equity $1.07B
• Jun 30, 2025: cash $53.7M, total assets $1.29B, total liabilities $118M, shareholders' equity $1.17B
• Mar 31, 2025: cash $94.6M, total assets $1.36B, total liabilities $107M, shareholders' equity $1.25B
• Dec 31, 2024: cash $265M, total assets $1.43B, total liabilities $110M, shareholders' equity $1.32B
• Sep 30, 2024: cash $317M, total assets $937M, total liabilities $104M, shareholders' equity $833M

What is CRNX's revenue?

Crinetics Pharmaceuticals, Inc. reported $42.2M of revenue over its last four quarters, through June 30, 2026.

Is CRNX profitable?

No. Crinetics Pharmaceuticals, Inc. lost $502M over the last four quarters.

What is CRNX's EPS?

Diluted earnings per share over the last four quarters were −$5.05; −$1.14 in the latest quarter.

CRNX ownership and insider trades · All stocks